AD
Therapeutic Areas
Pharma Mar Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Yondelis (trabectedin) | Soft Tissue Sarcoma | Approved |
| Zepzelca (lurbinectedin) | Metastatic Small Cell Lung Cancer (2nd line+) | Approved |
| Lurbinectedin | Small Cell Lung Cancer (Confirmatory Trial) | Phase 3 |
| PM54 (Zalypsis) | Multiple Myeloma | Phase 1/2 |
| Aplidin (plitidepsin) | Multiple Myeloma | Approved |
Leadership Team at Pharma Mar
JM
José María Fernández Sousa-Faro
Founder, President and Chief Executive Officer (CEO)
LM
Luis Mora
Chief Operating Officer (COO)
CB
Carlos Buesa
Former Chief Executive Officer
PD
Pablo de Miguel
Chief Scientific Officer (CSO)
AS
Arturo Soto
Director of Business Development
LG
Luis García
Director of Clinical Development